MTOR and non-small cell lung carcinoma: Despite AKT activating mutations being rare, AKT isoforms are overexpressed in NSCLC [54] and there are reports of efficacy with AKT inhibition as part of combination treatments in lung cancer patients [55], implying that there is potential for NSCLC patients to benefit from PI3K-AKT-mTOR targeted therapy.